| 郑华理,张 煌,周帅跃,等.阿帕替尼单药方案治疗210例进展期胃癌的疗效及预后影响因素分析[J].肿瘤学杂志,2022,28(4):280-284. |
| 阿帕替尼单药方案治疗210例进展期胃癌的疗效及预后影响因素分析 |
| Efficacy and Prognostic Factors of Apatinib Monotherapy in the Treatment for 210 Cases with Advanced Gastric Cancer |
| 投稿时间：2021-12-22 |
| DOI：10.11735/j.issn.1671-170X.2022.04.B005 |
|
 |
| 中文关键词: 阿帕替尼 胃癌 疗效 预后 影响因素 |
| 英文关键词:apatinib gastric cancer efficacy prognosis influencing factors |
| 基金项目: |
|
| 摘要点击次数: 902 |
| 全文下载次数: 259 |
| 中文摘要: |
| 摘 要：［目的］ 探讨阿帕替尼单药方案治疗进展期胃癌的疗效及预后影响因素。［方法］ 回顾性分析210例接受阿帕替尼单药治疗的晚期胃癌患者临床资料，总结近期疗效、生存时间及安全性指标，评价阿帕替尼单药治疗晚期胃癌的预后影响因素。［结果］ 210例患者治疗后客观缓解率和疾病控制率分别为5.71%和65.71%；中位无进展生存时间为73.0 d；≥3级不良反应包括：高血压6例，合并手足综合征10例，蛋白尿4例，腹泻4例，血小板减少7例，疲倦2例，出血4例。单因素分析显示，PS评分、给药剂量、合并手足综合征、高血压、蛋白尿、腹泻及AFP水平与阿帕替尼单药治疗晚期胃癌疾病控制率有关（P<0.05）；多因素分析显示，PS评分、合并手足综合征、高血压及AFP水平是阿帕替尼单药治疗晚期胃癌疾病控制率独立影响因素（P<0.05）。单因素分析显示，年龄、PS评分、给药剂量、合并手足综合征、高血压、蛋白尿及AFP水平与阿帕替尼单药治疗晚期胃癌无进展生存时间有关（P<0.05）；多因素分析结果显示，PS评分、给药剂量、合并手足综合征、高血压及AFP水平是阿帕替尼单药治疗晚期胃癌无进展生存时间的独立影响因素（P<0.05）。［结论］ 阿帕替尼单药治疗晚期胃癌疾病控制效果与PS评分、合并手足综合征、高血压及AFP水平密切相关；PS评分、给药剂量、合并手足综合征、高血压及AFP水平能够独立影响患者无进展生存时间。 |
| 英文摘要: |
| Abstract： ［Objective］ To investigate the efficacy and the prognostic factors of apatinib monotherapy in the treatment for advanced gastric cancer. ［Methods］ Clinical data of 210 stage Ⅳ gastric cancer treated with apatinib monotherapy were retrospectively analyzed. The clinical efficacy， survival time and safety indexes were analyzed and the prognostic factors of apatinib monotherapy for stage Ⅳ gastric cancer were evaluated. ［Results］ The objective response rate and disease control rate of 210 patients after treatment were 5.71% and 65.71%， respectively； the median progression free survival time was 73.0 d. Grade 3 adverse reactions included hypertension(n=6)， combined hand-foot syndrome(n=10)， proteinuria(n=4)， diarrhea(n=4)， thrombocytopenia(n=7)， fatigue(n=2) and bleeding(n=4). Univariate analysis showed that PS score， dosage， combined hand-foot syndrome， hypertension， proteinuria， diarrhea and AFP levels were associated with the disease control rate of stage Ⅳ gastric cancer treated with apatinib monotherapy(P<0.05). Multivariate analysis showed that PS score， combined hand-foot syndrome and hypertension and AFP levels were independent influencing factors for disease control rate of stage Ⅳ gastric cancer treated with apatinib monotherapy(P<0.05). Univariate analysis showed that age， PS score， dosage， hypertension， combined hand-foot syndrome， proteinuria and AFP levels were associated with progression free survival in patients with stage Ⅳ gastric cancer(P<0.05). Multivariate analysis showed that PS score， dosage， combined hand-foot syndrome， hypertension and AFP levels were independent factors of progression free survival in patients with stage Ⅳ gastric cancer(P<0.05). ［Conclusion］ The disease control effect of apatinib monotherapy in patients with stage Ⅳ gastric cancer is closely related to PS score， combined hand-foot syndrome， hypertension and AFP levels； PS score， dosage， combined hand-foot syndrome， hypertension and AFP levels can independently affect progression free survival time. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|